LDS/Medical Tests/Biopsy, Sentinel Lymph Node

Biopsy, Sentinel Lymph Node

Sentinel lymph node biopsy is a test in which a single, or sometimes several, lymph nodes are removed and assessed, usually by frozen section for metastatic malignancy. The sentinel lymph node is the first node in the lymphatic drainage of a tumor and the test is used mostly for cancer of the breast and malignant melanoma. The aim of this test is to reduce the morbidity of lymphedema following dissection of all of the nodes draining the area of a tumor (regional node dissection). In theory, if the first drainage node is negative, there is a high likelihood that the tumor has not metastasized and no further nodes need be removed, so sparing the patient lymphedema of a full regional node dissection.

It has been shown that about nine percent of patients with negative sentinel nodes have a positive node further along the nodal drainage chain (false negative), and furthermore, that about twenty percent with negative sentinel nodes will develop metastatic disease at some point. Success rate for this procedure is 90 – 95%; occasionally sentinel nodes are not found despite good localization technique. Still, the great majority of patients undergoing this procedure are spared the longterm effects of lymphedema, which include occasional cases of angiosarcoma. In breast cancer, the patient should have a diagnosis of infiltrating (invasive) breast carcinoma to qualify for this procedure. In melanoma, patients should have a diagnosis of infiltrating melanoma measuring more than 1.0 mm in thickness to qualify for SLN mapping.

Sentinel Lymph Node Biopsy is aimed at preventing the long term consequences of lymphedema due to complete regional node dissection following a diagnosis of infiltrating mammary carcinoma or infiltrating malignant melanoma. These consequences include lymphangitis, disfigurement, fungal infection, loss of range of motion and angiosarcoma.

Most common IHC markers are as follow: CD5, a transmembrane protein, Cyclin-dependent kinase inhibitor 1B (p27, Kip1), also known as CDKN1B, The combination of HMB-45, MART-1, and tyrosinase make this antibody combination a first-order pan melanoma screener, and it may prove to be a valuable marker for melanoma metastasis in sentinel lymph nodes.

  • Diagnosis of infiltrating mammary carcinoma
  • Diagnosis of infiltrating malignant melanoma
  • As an aid in diagnosis of lymphangitis, fungal infection
  • As ana aid in diagnosis of angiosarcoma
Sentinel nodes are read as "negative" if there is no evidence of metastatic neoplasm and "positive" if metastatic neoplasm is present. *Note: Rarely, there is a discrepancy between the Frozen section diagnosis and the final pathologic diagnosis.  This is usually due to microscopic metastatic tumor too small to be seen on frozen section, but later identified by special immunohistochemistry staining techniques.*

Negative lymph node by H&E light microscopy and immunohistochemistry microscopy.
 

 

Two to six hours prior to surgery a dose of 99Tc is infiltrated into the tumor area. About ten minutes prior to node biopsy, isosulfan blue (a blue dye) is also infiltrated. At the time of biopsy, a gamma probe is used to localize the sentinel node and an incision is made. The blue dye will usually highlight the lymphatic channels and the sentinel node and this is confirmed with the gamma probe. The node is then removed by the surgeon and sent to the Pathology laboratory for examination, usually by an immediate H&E stained frozen section.  Following frozen section, the tissue is prepared for routine H&E light microscopy and immunohistochemistry microscopy if the Frozen section slides were negative.  Immunohistochemistry can detect tumor cells too inconspicuous to be seen by the routine H&E stain.  Sometimes two or more sentinel nodes are found and submitted. If the frozen section report is "negative" the surgeon stops the procedure and continues with the breast tumor excision. If the frozen report is "positive" the surgeon performs a complete regional node dissection before proceeding to tumor excision.

Sentinel nodes are usually submitted fresh to the Pathology laboratory for frozen section, followed by paraffin embedding. Rarely no frozen is done and they are placed directly in fixative for routine processing.

Immunohistochemistry microscopy using pancytokeratin (for breast cancer) or MART-1 (for melanoma), Circulating tumor cell detection test.
Twenty minutes for Frozen section report, twenty-four hours for routine light microscopy, 24 - 72 hours for immunohistochemistry microscopy.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login